Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company utilizes a proprietary tri-complex inhibitor platform to target the active (ON) state of RAS proteins, which were historically considered 'undruggable.' Their approach aims to provide high selectivity and potency against specific RAS mutations while sparing healthy tissue. The company's strategy involves building a deep pipeline of RAS(ON) inhibitors that can be used as monotherapies or in combination regimens to overcome adaptive resistance. Headquartered in Redwood City, California, Revolution Medicines has rapidly advanced multiple candidates into late-stage clinical development, positioning itself as a leader in the RAS-targeting therapeutic landscape.